
Sign up to save your podcasts
Or


Send us Fan Mail
Javonte Maynor joins family doctor and medical marijuana expert Dr. Erich Schramm to discuss the changing space of marijuana research and medical marijuana in the United States. The duo discuss the frustration with politics entering the medical space when it comes to marijuana, and how changing administrations can delay research. The two get into the nuts and bolts of marijuana research, including the hoops needed to perform research, conditions being treated, and a study that may be coming soon. Dr. Schramm also explains his role prescribing marijuana for the last several years and what that entails from a legal standpoint. The two then imagine what may happen to these processes if marijuana is rescheduled from a Schedule 1 to a prescribable Schedule 3 drug; including to dispensaries, the pharmaceutical industry, and current prescribing doctors.
Be a part of advancing science by participating in clinical research.
Have a question for Dr. Koren? Email him at [email protected]
Listen on Spotify
Listen on Apple Podcasts
Watch on YouTube
Share with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.
Follow us on Social Media:
Facebook
Instagram
X (Formerly Twitter)
LinkedIn
Want to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.com
Music: Storyblocks - Corporate Inspired
Thank you for listening!
By Dr. Michael Koren5
77 ratings
Send us Fan Mail
Javonte Maynor joins family doctor and medical marijuana expert Dr. Erich Schramm to discuss the changing space of marijuana research and medical marijuana in the United States. The duo discuss the frustration with politics entering the medical space when it comes to marijuana, and how changing administrations can delay research. The two get into the nuts and bolts of marijuana research, including the hoops needed to perform research, conditions being treated, and a study that may be coming soon. Dr. Schramm also explains his role prescribing marijuana for the last several years and what that entails from a legal standpoint. The two then imagine what may happen to these processes if marijuana is rescheduled from a Schedule 1 to a prescribable Schedule 3 drug; including to dispensaries, the pharmaceutical industry, and current prescribing doctors.
Be a part of advancing science by participating in clinical research.
Have a question for Dr. Koren? Email him at [email protected]
Listen on Spotify
Listen on Apple Podcasts
Watch on YouTube
Share with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.
Follow us on Social Media:
Facebook
Instagram
X (Formerly Twitter)
LinkedIn
Want to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.com
Music: Storyblocks - Corporate Inspired
Thank you for listening!

229,674 Listeners

43,687 Listeners

9,724 Listeners

11,904 Listeners

8,876 Listeners

3,470 Listeners

12,741 Listeners

1,600 Listeners

20,222 Listeners

12,559 Listeners